Clearing the Air: A Review of Our Current Understanding of “Chemo Fog”
- 13 March 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Oncology Reports
- Vol. 15 (3), 260-269
- https://doi.org/10.1007/s11912-013-0307-7
Abstract
An increasing number of cancer survivors has led to a greater interest in the long-term side effects of cancer treatments and their impact on quality of life. In particular, cognitive impairments have been frequently reported by cancer survivors as an adverse effect which they attribute to the neurotoxicity of chemotherapy and have dubbed "chemobrain" or "chemo fog." Research within the past 15-20 years has explored the many factors thought to contribute to cancer-related cognitive decline in an attempt to determine a potential cause. In spite of many confounding factors, there is growing evidence that the neurotoxicity of chemotherapy does contribute to cognitive changes. This review examines the evolution of "chemo fog" research with a look at methodological issues, the status of our current understanding, and suggestions for future research.Keywords
This publication has 90 references indexed in Scilit:
- Prefrontal Cortex and Executive Function Impairments in Primary Breast CancerArchives of Neurology, 2011
- Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trialBreast Cancer Research and Treatment, 2010
- Longitudinal Assessment of Cognitive Changes Associated With Adjuvant Treatment for Breast Cancer: Impact of Age and Cognitive ReserveJournal of Clinical Oncology, 2010
- Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI studyBreast Cancer Research and Treatment, 2010
- Cognitive speed of processing and functional declines in older cancer survivors: an analysis of data from the ACTIVE trialEuropean Journal of Cancer Care, 2009
- Cognitive and Psychological Factors Associated with Early Posttreatment Functional Outcomes in Breast Cancer SurvivorsJournal of Psychosocial Oncology, 2009
- Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care responseJournal of Cancer Survivorship, 2009
- ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapyClinical Neurophysiology, 2008
- Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancerMenopause, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005